Business
Amarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood Diagnostic LymPro Test 2.0 Blood Test vs. Amyloid PET
Amarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood Diagnostic LymPro Test 2.0 Blood Test vs. Amyloid PET.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\nNEW YORK, May 04, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the \"Company\" or AMBS), a US-based JLABS-alumnus biotechnology holding company, developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that it has entered into an exclusive option agreement with Leipzig University. The exclusive option agreement allows the Company to license rights to \"LymPro Test 2.0\" which incorporates LymPro Test results with those of amyloid PET imaging for the diagnosis of Alzheimer's disease.\n Under the terms of the agreement, Amarantus acquired an exclusive option to evaluate data produced from a German-based clinical study (LymPro PET 1) initiated in 2016 and completed in 2017 under the supervision of Dr. Thomas Arendt, the inventor of LymPro Test. Amarantus received a summary of the data on May 2, 2018. Upon exercising the Company's exclusive option, Amarantus and Leipzig will complete negotiations to license LymPro IP and data created from LymPro PET 1 to Amarantus, and collaborate on a confirmatory 20 subject trial (LymPro PET 2) currently enrolling under Dr. Arendt's supervision. AAIC 2015 Poster Presentation of LymPro Test LP-002 Clinical Data Amarantus Alzheimer's Diagnostics Scientific Advisory Board Dr. Ropacki Appointed Chief Medical Advisor for Alzheimer's Blood Diagnostic LymPro Test About Alzheimer's Disease According to the Alzheimer's Association, it is estimated that over 5.4 million people in the United States suffer from Alzheimer's disease. Over 500,000 patients are diagnosed annually, with nearly one-in-eight older Americans affected by the disease. Alzheimer's disease is the third leading cause of death in the United States. The cost of unpaid care in the United States is estimated at over $210 billion annually. Total payments for care are estimated at over $200 billion annually, including $140 billion in cost to Medicare and Medicaid. Alzheimer's expenditures in the United States are expected to exceed $1.2 trillion by 2050. There is no cure or effective treatment for Alzheimer's disease. Worldwide, about 35.6 million individuals have the disease and, according to the World Health Organization, the number will double every 20 years to 115.4 million people with Alzheimer'...